CPT2在肾透明细胞癌中的表达及临床意义  

Expression and clinical significance of CPT2 in renal clear cell carcinoma

作　　者：高幸福 关翰 闫瑞莲 凌能勇 罗文豪 汪盛[1] GAO Xingfu;GUAN Han;YAN Ruilian;LING Nengyong;LUO Wenhao;WANG Sheng(Department of Urology Surgery,the First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui 233004,China)

机构地区：[1]蚌埠医学院第一附属医院泌尿外科,安徽蚌埠233004

出　　处：《中华全科医学》2023年第7期1243-1247,共5页Chinese Journal of General Practice

基　　金：安徽省自然科学基金项目(2008085QH358)。

摘　　要：目的探讨肉碱棕榈酰转移酶2(CPT2)在肾透明细胞癌(ccRCC)中的差异化表达以及与临床预后的相关性,为ccRCC的诊治提供新的生物治疗靶点和理论依据。方法首先筛选肿瘤基因组图谱(TCGA)数据,从中获得目的基因CPT2。随后利用R软件分析该基因的差异化表达结果。通过R软件对TCGA下载的临床数据及预后情况进行分析,并绘制可视化图表。利用免疫组化研究该基因在ccRCC组织及癌旁组织中的差异化表达,以及与临床数据的相关性。结果利用R软件对TCGA数据库样本分析得出:CPT2在癌旁组织的表达高于癌组织(P<0.05)。不同年龄及N分期的患者CPT2表达的差异无统计学意义(均P>0.05),不同性别、T分期、M分期、临床分期、病理分级及总生存期的患者CPT2表达的差异有统计学意义(均P<0.05)。免疫组化结果表明:CPT2在癌旁组织中的表达率(100.0%,16/16)高于ccRCC组织(39.7%,23/58,P<0.001)。不同临床分期患者CPT2比较差异有统计学意义(P<0.05),不同性别、T分期、病理分级、M分期、年龄患者CPT2比较差异无统计学意义(均P>0.05)。CPT2的KEGG通路主要为脂肪细胞因子信号通路、胰高血糖素信号通路、脂肪酸降解、脂肪酸代谢、过氧化物酶体增殖物激活受体(PPAR)信号通路等。结论CPT2在肾透明细胞癌中可能是一个抑癌基因,这也许可以作为肾透明细胞癌早期筛查及治疗的潜在生物靶点,为肾透明细胞癌的预防与治疗带来新的方案和方向。Objective To investigate the differential expression of carnitine palmitoyltransferase 2(CPT2)in renal clear cell carcinoma(ccRCC)and its correlation with clinical prognosis,in order to provide a new biological therapy target and theoretical basis for the diagnosis and treatment of ccRCC.Methods The tumor genome atlas(TCGA)data were first screened to obtain the target gene CPT2.Subsequently,R software was used to analyze the differential expression results of the gene.The clinical data and prognosis downloaded from TCGA was analyzed by R software and visual charts was draw.Immunohistochemistry was used to study the differential expression of this gene in ccRCC tissues and paraneoplastic tissues.Immunohistochemistry was used to study the differential expression of gene in ccRCC tissues and paraneoplastic tissues,and the correlation with clinical data was analyzed.Results Using R software to analyze the TCGA database samples,it was found that the expression of CPT2 in paracancerous tissues was higher than that in cancerous tissues(P<0.05).There was no statistically significant difference in CPT2 expression among patients of different ages and N stages(all P>0.05).There were significant differences in CPT2 expression among patients with different gender,T stage,M stage,clinical stage,pathological grade and overall survival(all P<0.05).Immunohistochemical results showed that the expression rate of CPT2 in paracancerous tissues(100.0%,16/16)was higher than that in ccRCC tissues(39.7%,23/58,P<0.001).There was a statistically significant difference in CPT2 comparison among patients with different clinical stages(P<0.05),and there was no statistically significant difference in CPT2 comparison among patients with different gender,T stage,pathological grade,M stage,and age(all P>0.05).The KEGG pathway of CPT2 mainly included adipocyte factor signaling pathway,glucagon signaling pathway,fatty acid degradation,fatty acid metabolism,and PPAR signaling pathway,etc.Conclusion CPT2 may be a tumor suppressor gene in renal clear c

关 键 词：肾透明细胞癌 肉碱棕榈酰转移酶2 癌症基因组图谱数据库 生物信息学 

分 类 号：R737.11[医药卫生—肿瘤] R730[医药卫生—临床医学]